Piper Sandler Initiates Coverage On Skye Bioscience with Overweight Rating, Announces Price Target of $12
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Edward Tenthoff has initiated coverage on Skye Bioscience (OTC:SKYE) with an Overweight rating and set a price target of $12. This move could indicate a positive outlook on SKYE's future performance.
February 05, 2024 | 12:11 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Piper Sandler has initiated coverage on Skye Bioscience with an Overweight rating and a price target of $12, suggesting a positive outlook.
The initiation of coverage by a reputable analyst with an Overweight rating and a significant price target suggests a strong bullish sentiment towards SKYE. This could lead to increased investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100